|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Natural history/Epidemiology
|
|
|
|
Completed
|
|
|
|
18 to 65
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
0903X-100847 NCT00161668
|
|
|
|
|
|
|
|
Last Modified: 1/10/2007  First Published: 8/24/2004 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
61 and over
|
|
|
|
Other
|
|
|
|
EORTC-06031 NCT00091234
|
|
|
|
|
|
|
|
Last Modified: 8/16/2007  First Published: 11/24/2002 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
61 to 75
|
|
|
|
Other
|
|
|
|
EORTC-06012 AML-17, NCT00052299, GIMEMA-AML-17
|
|
|
|
|
|
|
|
Last Modified: 5/28/2007  First Published: 7/15/2005 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
61 and over
|
|
|
|
Other
|
|
|
|
SAKK-AML-43 EU-20514, HOVON-AML-43, NCT00121303
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
21 and under
|
|
|
|
NCI, Other
|
|
|
|
AMLO2 NCT00136084
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
55 to 75
|
|
|
|
Other
|
|
|
|
ID01-010 NCT00038831
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
KAN-979-02 NCT00233909
|
|
|
|
|
|
|
|
Last Modified: 8/17/2007  First Published: 2/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
W-AR-0903B1-201-US UCCRC-8600, NCI-V97-1355, NCT00003131
|
|
|
|
|
|
|
|
Last Modified: 8/17/2007  First Published: 4/1/1999 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
60 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
W-AR-0903B1-203-US NCI-V98-1497, NCT00003673
|
|
|
|
|
|
|
|
Last Modified: 6/12/2007  First Published: 7/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
E-4999 NCT00005962, E4999
|
|
|
|